STERIS plc STE
- Market cap
- $20.4B
- P/E
- 25.4×
Follow STE
STERIS plc (STE) Price to free cash flow
As of 25 September 2026, STERIS plc (STE) trades at a price to free cash flow of 21.8×. Over the past ten years it has ranged from 13.8× (June 2015) to 61.8× (April 2022); the current reading is higher than 12% of that period. That is in line with the Medical Devices industry median of 22.5× and above the Healthcare sector median of 19.5×.
Price to free cash flow, daily
Annual
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2026 | 22.1× | (22.18%) |
| FY2025 | 28.4× | (19.35%) |
| FY2024 | 35.2× | (24.41%) |
| FY2023 | 46.6× | (21.21%) |
| FY2022 | 59.1× | 64.22% |
| FY2021 | 36.0× | 15.31% |
| FY2020 | 31.2× | 2.91% |
| FY2019 | 30.3× | 15.32% |
| FY2018 | 26.3× | 13.42% |
| FY2017 | 23.2× | (40.40%) |
Quarterly
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 22.0× | (0.62%) |
| Mar 2026 | 22.1× | (16.88%) |
| Dec 2025 | 26.6× | 5.93% |
| Sep 2025 | 25.1× | (2.55%) |
| 42 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 6.0× |
| PHG Koninklijke Philips N.V. compare | 12.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 16.9× |
| GEHC GE HealthCare Technologies Inc. compare | 19.1× |
| STE STERIS plc | 21.8× |
| DXCM DexCom, Inc. compare | 23.6× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 27.5× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.7× |
| PEN Penumbra, Inc. compare | 58.1× |
| Medical Devices industry median | 22.5× |
| Healthcare sector median | 19.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on STE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement